Publications 2017

Jorgensen SF, Macpherson ME, Bjoro K, Karlsen TH, Reims HM, Grzyb K, Fosby B, Fevang B, Aukrust P, Nordoy I (2017)
Liver transplantation in patients with primary antibody deficiency
J. Allergy Clin. Immunol., 139 (5), 1708-+
DOI 10.1016/j.jaci.2016.10.025

Publications 2015

Dalgard O, Martinot-Peignoux M, Verbaan H, Bjoro K, Ring-Larsen H, Marcellin P (2015)
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection
PLoS One, 10 (8), e0120866
DOI 10.1371/journal.pone.0120866

Fosby B, Melum E, Bjoro K, Bennet W, Rasmussen A, Andersen IM, Castedal M, Olausson M, Wibeck C, Gotlieb M, Gjertsen H, Toivonen L, Foss S, Makisalo H, Nordin A, Sanengen T, Bergquist A, Larsson ME, Soderdahl G, Nowak G, Boberg KM, Isoniemi H, Keiding S, Foss A, Line PD et al. (2015)
Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013
Scand. J. Gastroenterol., 50 (6), 797-808
DOI 10.3109/00365521.2015.1036359

Publications 2014

Eskesen AN, Bjoro K, Aandahl EM, Line PD, Melum E (2014)
Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway-A population-based cohort study
Cancer Epidemiol., 38 (6), 741-747
DOI 10.1016/j.canep.2014.10.005

Publications 2012

Eskesen AN, Melum E, Moghaddam A, Bjoro K, Verbaan H, Ring-Larsen H, Dalgard O (2012)
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort
Eur. J. Gastroenterol. Hepatol., 24 (8), 890-896
DOI 10.1097/MEG.0b013e3283546efd

Publications 2011

Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K, Dalgard O (2011)
IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection
Hepatology, 53 (3), 746-754
DOI 10.1002/hep.24154

Publications 2010

Bjoro K (2010)
This month in Scandinavian Journal of Gastroenterology
Scand. J. Gastroenterol., 45 (6), 643-644
DOI 10.3109/00365521.2010.488881

Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damas JK, Haaland T, Loberg EM, Arntsen B, Birkeland K, Bjoro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B (2010)
Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease
J. Clin. Endocrinol. Metab., 95 (6), 3039-3047
DOI 10.1210/jc.2009-2148

Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H (2010)
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
Eur. J. Gastroenterol. Hepatol., 22 (5), 552-556
DOI 10.1097/MEG.0b013e328335b29e

Publications 2009

Haukeland JW, Konopski Z, Eggesbo HB, Von Volkmann HL, Raschpichler G, Bjoro K, Haaland T, Loberg EM, Birkeland K (2009)
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Scand. J. Gastroenterol., 44 (7), 853-860
DOI 10.1080/00365520902845268

Yndestad A, Haukeland JW, Dahl TB, Bjoro K, Gladhaug IP, Berge C, Damas JK, Haaland T, Loberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P (2009)
A Complex Role of Activin A in Non-Alcoholic Fatty Liver Disease
Am. J. Gastroenterol., 104 (9), 2196-2205
DOI 10.1038/ajg.2009.318

Publications 2008

Bjoro K (2008)
This month in Scandinavian Journal of Gastroenterology
Scand. J. Gastroenterol., 43 (6), 643-644
DOI 10.1080/00365520802125191

Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelof B, Ritland S, Hellum K, Fryden A, Florholmen J, Verbaan H, Grp, NC (2008)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Hepatology, 47 (1), 35-42
DOI 10.1002/hep.21975

Publications 2007

Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, Bang C, Raknerud N, Konopski Z (2007)
Incidence rates and causes of cirrhosis in a Norwegian population
Scand. J. Gastroenterol., 42 (12), 1501-1508
DOI 10.1080/00365520701478014

Melum E, Friman S, Bjoro K, Rasmussen A, Isoniemi H, Gjertsen H, Backman L, Oksanen A, Olausson M, Duraj FF, Ericzon BG (2007)
Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma
J. Hepatol., 47 (6), 777-783
DOI 10.1016/j.jhep.2007.06.013

Publications 2006

Andriulli A, Dalgard O, Bjoro K, Mangia A (2006)
Short-term treatment duration for HCV-2 and HCV-3 infected patients
Dig. Liver Dis., 38 (10), 741-748
DOI 10.1016/j.dld.2006.06.006

Bjoro K, Brandsaeter B, Foss A, Schrumpf E (2006)
Liver transplantation in primary sclerosing cholangitis
Semin. Liver Dis., 26 (1), 69-79
DOI 10.1055/s-2006-933565

Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P (2006)
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
J. Hepatol., 44 (6), 1167-1174
DOI 10.1016/j.jhep.2006.02.011

Melum E, Schrumpf E, Bjoro K (2006)
Liver TX for hepatitis C cirrhosis in a low prevalence population: Risk factors and status at evaluation
Scand. J. Gastroenterol., 41 (5), 592-596
DOI 10.1080/00365520500347113

Publications 2005

Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Kirkegaard P, Friman S, Bjoro K, Schrumpf E, Nordic Liver Transplantation Grp (2005)
Chernopreventive effect of ursodeoxycholic acid in primary sclerosing cholangitis?
FALK SYMP, 141, 242-249

Brandsaeter B, Schrumpf E, Bentdal O, Brabrand K, Smith HJ, Abildgaard A, Clausen OP, Bjoro K (2005)
Recurrent primary sclerosing cholangitis after liver transplantation: A magnetic resonance cholanglography study with analyses of predictive factors
Liver Transplant., 11 (11), 1361-1369
DOI 10.1002/lt.20444

Haukeland JW, Konopski Z, Linnestad P, Azimy S, Loberg EM, Haaland T, Birkeland K, Bjoro K (2005)
Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Scand. J. Gastroenterol., 40 (12), 1469-1477
DOI 10.1080/00365520500264953

Publications 2004

Bjoro K, Schrumpf E (2004)
Liver transplantation for primary sclerosing cholangitis
J. Hepatol., 40 (4), 570-577
DOI 10.1016/j.jhep.2004.01.021

Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
Hepatology, 40 (6), 1260-1265
DOI 10.1002/hep.20467

Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
In Hepatology, Wiley, New York, 40(2004)6, S. 1260-5
BIBSYS 051781174

Rikshospitalet, Aabakken L, Bjøro K (2004)
Metodebok for leger, Medisinsk avdeling
Medisinsk avdeling, Rikshospitalet, [Oslo] (Utg. 2), 152 s.
BIBSYS 050477226

Publications 2003

Bjoro K, Brandsaeter B, Wiencke K, Bjoro T, Godang K, Bollerslev J, Schrumpf E (2003)
Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease
Scand. J. Gastroenterol., 38 (3), 320-327
DOI 10.1080/00365520310000681

Bjoro K, Ericzon BG, Kirkegaard P, Hockerstedt K, Soderdahl G, Olausson M, Foss A, Schmidt LE, Isoniemi H, Brandsaeter B, Friman S (2003)
Highly urgent liver transplantation: Possible impact of donor-recipient ABO matching on the outcome after transplantation
Transplantation, 75 (3), 347-353
DOI 10.1097/01.TP.0000044359.72379.E5

Bjøro K, Brandsæter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E (2003)
Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 38(2003)3, s.320-7
BIBSYS 041707508

Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Backman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Kirkegaard P, Bjoro K (2003)
Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries
Scand. J. Gastroenterol., 38 (11), 1176-1183
DOI 10.1080/00365520310006009

Brandsater B, Broome U, Isoniemi H, Friman S, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Olsson R, Olausson M, Kirkegaard P, Bjoro K (2003)
Liver transplantation for primary sclerosing cholangitis in the Nordic countries: Outcome after acceptance to the waiting list
Liver Transplant., 9 (9), 961-969
DOI 10.1053/jlts.2003.50169

Dalgard O, Skaug K, Ritland S, Myrvang B, Hellum K, Bjøro K, Bell H (2003)
Short treatment (14 weeks) with pegylated interferon alpha-2B and ribavirin for the treatment of hepatitis C genotype 2/3 infection
In Journal of hepatology, Munksgaard, København, 38(2003)Suppl 2, s.134-5
BIBSYS 041707680

Moen EM, Sagedal S, Bjoro K, Degre M, Opstad PK, Grinde B (2003)
Effect of immune modulation on TT virus (TTV) and TTV-Like-Mini-Virus (TLMV) viremia
J. Med. Virol., 70 (1), 177-182
DOI 10.1002/jmv.10356

Publications 2002

Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Doskeland B, Maeland A, Lund-Tonnesen S, Myrvang B (2002)
Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study
Scand. J. Gastroenterol., 37 (2), 226-232
DOI 10.1080/003655202753416920

Bjoro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Storseth S, Ritland S, Lund-Tonnesen S, Bucher A, Hellum KB (2002)
Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection - A randomized multicentre study
Scand. J. Gastroenterol., 37 (3), 344-349
DOI 10.1080/003655202317284264

Bjøro K, Bell H, Hellum K, Skaug K, Raknerud N, Sandvei P, Døskeland B, Mæland A, Lund-Tønnesen S, Myrvang B (2002)
Effect of combined interferon-alpha induction therapy andribavirin on chronic hepatitis C virus infection: a randomized multicentre study
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 2, s. 226-232
BIBSYS 031205933

Bjøro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Storseth S, Ritland S, Lund-Tønnesen S, Bucher A, Hellum K (2002)
Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 3, s. 344-349
BIBSYS 03120550x

Brandsaeter B, Hockerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H, Olausson M, Broome U, Schmidt L, Foss A, Bjoro K (2002)
Fulminant hepatic failure: Outcome after listing for highly urgent liver transplantation - 12 years experience in the Nordic countries
Liver Transplant., 8 (11), 1055-1062
DOI 10.1053/jlts.2002.35556

Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H (2002)
Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy
J. Intern. Med., 251 (5), 400-406
DOI 10.1046/j.1365-2796.2002.00974.x

Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H, Construct Grp (2002)
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
Eur. Addict. Res., 8 (1), 45-49
DOI 10.1159/000049487

Dalgard O, Bjøro K, Hellum K, Bell H (2002)
Behandling ved kronisk hepatitt C
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 122(2002)nr. 9, S. 926-8
BIBSYS 031200362

Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (2002)
Thyroid dysfunction during treatment of chronic hepatitisC with interferon alpha: no association with wither dosage or efficacy of therapy
In Journal of internal medicine, Blackwell Scientific Publ., Oxford, 251(2002)nr 5, s. 400-406
BIBSYS 031206328

Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H (2002)
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
In European addiction research, Karger, Basel, 8(2002)nr 1, s. 45-49
BIBSYS 031206530

Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H (2002)
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection
Liver, 22 (3), 269-275
DOI 10.1046/j.0106-9543.2002.01672.x

Distante S, Bjøro K, Hellum K, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H (2002)
Raised serum ferritin predicts non-response to interferonand ribavirin treatment in patients with chronic hepatitis C-infection
In Journal of hepatology, Munksgaard, København, 36(2002)Suppl 1, s. 233
BIBSYS 03142631x

Publications 2001

Bjoro K, Kirkegaard P, Ericzon BG, Friman S, Schrumpf E, Isoniemi H, Herlenius G, Olausson M, Rasmussen A, Foss A, Hockerstedt K (2001)
Is a 3-day limit for highly urgent liver transplantation for fulminant hepatic failure appropriate, and is the diagnosis in some cases incorrect?
Transplant. Proc., 33 (4), 2511-2513
DOI 10.1016/S0041-1345(01)02080-2

Bjoro K, Petrova EP, Thomas MG, Froland SS, Williams R, Naoumov NV (2001)
TT virus infection in patients with primary hypogammaglobulinaemia: Natural history and relationship to liver disease in the immunocompromised host
Scand. J. Gastroenterol., 36 (9), 987-993
DOI 10.1080/003655201750305530

Ericzon BG, Bjoro K, Hoeckerstedt K, Hanssen B, Olausson M, Isoniemi H, Kirkegaard P, Soderdahl G, Foss A, Friman S (2001)
Time to request ABO-identity when transplanting for fulminant hepatic failure?
Transplant. Proc., 33 (7-8), 3466-3467
DOI 10.1016/S0041-1345(01)02493-9

Publications 2000

Bjøro K, Bell H, Hellum K, Myrvang B, Skaug K (2000)
Randomized trial of IFN-A induction and ribavirin vs standard IFN-A and ribavirin for chronic HCV in perviously untreated patients
In Hepatology, Wiley, New York, 32(2000)nr 4 del 2, s.317A
BIBSYS 010838090

Dalgard O, Bjøro K, Myrvang B, Hellum K, Skaug K, Gutigard B, Bell H (2000)
Long-term follow-up after treatment of chronic hepatitis C with interferon-A: Reinfection in injecting drug users
In Hepatology, Wiley, New York, 32(2000)nr 4 del 2, s.359A
BIBSYS 01080109x

Publications 1999

Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjoro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P, CONSTRUCT Grp (1999)
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
Scand. J. Gastroenterol., 34 (2), 194-198

Bjoro K, Friman S, Hockerstedt K, Kirkegaard P, Keiding S, Schrumpf E, Olausson M, Oksanen A, Isoniemi H, Hjortrup A, Bergan A, Ericzon BG (1999)
Liver transplantations in the Nordic countries, 1982-1998: Changes of indications and improving results
Scand. J. Gastroenterol., 34 (7), 714-722

Bjoro K, Haaland T, Skaug K, Froland SS (1999)
The spectrum of hepatobiliary disease in primary hypogammaglobulinaemia
J. Intern. Med., 245 (5), 517-524
DOI 10.1046/j.1365-2796.1999.00457.x

Bjoro K, Skaug K, Haaland T, Froland SS (1999)
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia
QJM-An Int. J. Med., 92 (8), 433-441
DOI 10.1093/qjmed/92.8.433

Publications 1998

Bjoro K, Gjerstad L, Bentdal O, Osnes S, Schrumpf E (1998)
Topiramate and fulminant liver failure
Lancet, 352 (9134), 1119

Bjoro K, Schrumpf E, Bergan A, Haaland T, Skaug K, Froland SS (1998)
Liver transplantation for endstage hepatitis C cirrhosis in a patient with primary hypogammaglobulinaemia
Scand. J. Infect. Dis., 30 (5), 520-522

Publications 1997

Keiding S, Hockerstedt K, Bjoro K, Bondesen S, Hjortrup A, Isoniemi H, Erichsen C, Soderdahl G, Ericzon BG (1997)
The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients
Transplantation, 63 (11), 1591-1594
DOI 10.1097/00007890-199706150-00009

Odeberg J, Yun ZB, Sonnerborg A, Bjoro K, Uhlen M, Lundeberg J (1997)
Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients
J. Infect. Dis., 175 (4), 938-943
DOI 10.1086/513995

Publications 1996

Haugen G, StrayPedersen S, Bjoro K (1996)
The influence of angiotensin II on prostanoid production in preterm human umbilical arteries
Gynecol.Obstet.Invest., 42 (3), 159-162
DOI 10.1159/000291936

Publications 1995

BJORO K, FROLAND SS (1995)
HEPATITIS-C AND IMMUNE GLOBULIN - REPLY
N. Engl. J. Med., 332 (18), 1236

BJORO K, KRARUP H, BELL H, CHRISTOPHERSEN P, EVENSEN S, FROLAND SS, LAURSEN A, VANDERLIPPE B, MAELAND A, RANEK L, RINGLARSEN H, SCHOU G, SCHRUMPF E, TYGSTRUP N (1995)
2 DOSE REGIMENS OF RECOMBINANT INTERFERON-ALPHA-2B IN CHRONIC HEPATITIS-C VIRUS-INFECTION - BIOCHEMISTRY, HEPATITIS-C VIRUS RNA, AND LIVER HISTOLOGY AS RESPONSE INDICES
Scand. J. Gastroenterol., 30 (11), 1119-1124
DOI 10.3109/00365529509101617

BJORO K, SCHRUMPF E, ELGJO K, KOLMANSKOG F (1995)
MONSTROUS ASCITES IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
Scand. J. Gastroenterol., 30 (1), 92-94
DOI 10.3109/00365529509093242

HAUGEN G, STRAYPEDERSEN S, BJORO K (1995)
EFFECT OF PHENAZONE (ANTIPYRINE) ON THE PROSTANOID FORMATION IN HUMAN UMBILICAL ARTERIES PERFUSED IN-VITRO
Gynecol.Obstet.Invest., 39 (1), 8-10
DOI 10.1159/000292366

ROKKONES E, FROMM SH, KAREEM BN, KLUNGLAND H, OLSTAD OK, HOGSET A, IVERSEN J, BJORO K, GAUTVIK KM (1995)
HUMAN PARATHYROID-HORMONE AS A SECRETORY PEPTIDE IN MILK OF TRANSGENIC MICE
J. Cell. Biochem., 59 (2), 168-176
DOI 10.1002/jcb.240590206

SANDERUD J, OROSZLAN G, BJORO K, KUMLIN M, SAUGSTAD OD (1995)
D-PENICILLAMINE INHIBITS THE ACTION OF REACTIVE OXYGEN SPECIES IN THE PIG PULMONARY CIRCULATION
J. Perinat. Med., 23 (5), 385-393
DOI 10.1515/jpme.1995.23.5.385

Publications 1994

BJORO K, FROLAND SS, YUN ZB, SAMDAL HH, HAALAND T (1994)
HEPATITIS-C INFECTION IN PATIENTS WITH PRIMARY HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH CONTAMINATED IMMUNE GLOBULIN
N. Engl. J. Med., 331 (24), 1607-1611
DOI 10.1056/NEJM199412153312402

Bjøro K, Rose-Neil W, Marks I (1994)
Alt om svangerskapet: mor og barn uke for uke fra befruktning til fødsel
Schibsted, Oslo (4. rev. oppl.), 206 s.
BIBSYS 940192055, ISBN 82-516-1512-7

Publications 1993

PETERSEN PH, BLAABJERG O, IRJALA K, ICEN A, BJORO K (1993)
A MODEL FOR QUALITY ACHIEVEMENT - THE NORDKEM PROTEIN PROJECT
Scand. J. Clin. Lab. Invest., 53 212, 10-12
DOI 10.3109/00365519309085447

PETERSEN PH, BLAABJERG O, IRJALA K, ICEN A, BJORO K (1993)
EXTERNAL ANALYTICAL QUALITY ASSURANCE FOR PROTEINS
Ups. J. Med. Sci., 98 (3), 241-258
DOI 10.3109/03009739309179319

SANDERUD J, BJORO K, SAUGSTAD OD (1993)
OXYGEN RADICALS STIMULATE THROMBOXANE AND PROSTACYCLIN SYNTHESIS AND INDUCE VASOCONSTRICTION IN PIG LUNGS
Scand. J. Clin. Lab. Invest., 53 (5), 447-455
DOI 10.3109/00365519309092539

Publications 1992

HAUGEN G, STRAYPEDERSEN S, BJORO K (1992)
THE INFLUENCE OF BRADYKININ ON THE PROSTANOID PRODUCTION IN UMBILICAL ARTERIES IN PREECLAMPSIA
CLIN EXP HYPERTENS B, 11 (2-3), 147-163
DOI 10.3109/10641959209031040

Publications 1991

HAUGEN G, BJORO K, STRAYPEDERSEN S (1991)
THE INFLUENCE OF EXTRA-UMBILICAL SEROTONIN, PGE2 AND PGF2-ALPHA ON PROSTANOID PRODUCTION IN HUMAN UMBILICAL ARTERIES
Scand. J. Clin. Lab. Invest., 51 (2), 131-135
DOI 10.3109/00365519109091098

HAUGEN G, BJORO K, STRAYPEDERSEN S (1991)
VASOACTIVE EFFECTS OF INTRAVASCULAR AND EXTRAVASCULAR SEROTONIN, PGE2 AND PGF2-ALPHA IN HUMAN UMBILICAL ARTERIES
Gynecol.Obstet.Invest., 31 (4), 208-212
DOI 10.1159/000293160

Publications 1990

HAUGEN G, STRAYPEDERSEN S, BJORO K (1990)
VASOACTIVE-INTESTINAL-PEPTIDE AND PROSTANOID PRODUCTION IN NORMAL AND SINGLE UMBILICAL ARTERY CORDS IN NORMOTENSIVE AND HYPERTENSIVE PREGNANCIES
CLIN EXP HYPERTENS B, 9 (1), 69-80

HAUGEN G, STRAYPEDERSEN S, BJORO K (1990)
ANGIOTENSIN CONVERTING ENZYME AND ANGIOTENSIN STIMULATED PROSTANOID PRODUCTION IN THE UMBILICAL ARTERY IN PREECLAMPSIA
CLIN EXP HYPERTENS B, 9 (2), 135-150
DOI 10.3109/10641959009072251

HAUGEN G, STRAYPEDERSEN S, BJORO K (1990)
PROSTANOID PRODUCTION IN UMBILICAL ARTERIES FROM PRETERM AND TERM DELIVERIES PERFUSED INVITRO
Early Hum. Dev., 24 (2), 153-161
DOI 10.1016/0378-3782(90)90144-8

PETERSEN PH, BLAABJERG O, BJORO K, ICEN A, IRJALA K (1990)
THE NORDIC PROTEIN PROJECT
Ups. J. Med. Sci., 95 (3), 251-255
DOI 10.3109/03009739009178598

Publications 1988

BENTDAL OH, FROLAND SS, ASKEVOLD F, BJORO K, LARSEN S (1988)
NUTRITIONAL ASSESSMENT OF ANOREXIA-NERVOSA PATIENTS - ANALYSIS OF ANTHROPOMETRIC AND BIOCHEMICAL VARIABLES TO EVALUATE PATIENTS AT RISK
Clin. Nutr., 7 (2), 93-99
DOI 10.1016/0261-5614(88)90031-3

OIAN P, SKRAMM I, HANNISDAL E, BJORO K (1988)
BREECH DELIVERY - AN OBSTETRICAL ANALYSIS
Acta Obstet. Gynecol. Scand., 67 (1), 75-79
DOI 10.3109/00016348809004172

RIVRUD GN, MOEN M, MOE N, BERG K, BJORO K (1988)
MUTAGENICITY TESTING OF AMNIOTIC-FLUID FROM DIABETIC WOMEN, WITH SPECIAL REFERENCE TO THEIR SMOKING-HABITS
Gynecol.Obstet.Invest., 26 (2), 113-117
DOI 10.1159/000293681

STORMORKEN H, GJEMDAL T, BJORO K (1988)
LUPUS ANTICOAGULANT - A UNIQUE CASE WITH LUPUS ANTICOAGULANT AND HABITUAL ABORTION TOGETHER WITH ANTIFACTOR-II ANTIBODY AND BLEEDING TENDENCY
Gynecol.Obstet.Invest., 26 (1), 83-88
DOI 10.1159/000293678

Publications 1987

BJORO K, HAUGEN G, STRAYPEDERSEN S (1987)
ALTERED PROSTANOID FORMATION IN HUMAN UMBILICAL VASCULATURE IN RESPONSE TO VARIATIONS IN OXYGEN-TENSION
Prostaglandins, 34 (3), 377-384
DOI 10.1016/0090-6980(87)90083-9

Publications 1986

BJORO K (1986)
PROSTACYCLIN AND THROMBOXANE FORMATION IN HUMAN UMBILICAL ARTERIES FOLLOWING STIMULATION WITH VASOACTIVE AUTACOIDS
Prostaglandins, 31 (4), 699-714
DOI 10.1016/0090-6980(86)90175-9

BJORO K, HOVIG T, STOKKE KT, STRAYPEDERSEN S (1986)
FORMATION OF PROSTANOIDS IN HUMAN UMBILICAL VESSELS PERFUSED INVITRO
Prostaglandins, 31 (4), 683-698
DOI 10.1016/0090-6980(86)90174-7

BJORO K, STOKKE KT, STRAYPEDERSEN S (1986)
ALTERED ANGIOTENSIN-PROSTANOID INTERACTIONS IN UMBILICAL ARTERIES IN PREGNANCY-INDUCED HYPERTENSION
Scand. J. Clin. Lab. Invest., 46 184, 91-96

BJORO K, STRAYPEDERSEN S (1986)
INVITRO PERFUSION STUDIES ON HUMAN UMBILICAL ARTERIES .1. VASOACTIVE EFFECTS OF SEROTONIN, PGF2-ALPHA AND PGE2
Acta Obstet. Gynecol. Scand., 65 (4), 351-355
DOI 10.3109/00016348609157359

BJORO K, STRAYPEDERSEN S (1986)
EFFECTS OF VASOACTIVE AUTACOIDS ON DIFFERENT SEGMENTS OF HUMAN UMBILICOPLACENTAL VESSELS
Gynecol.Obstet.Invest., 22 (1), 1-6
DOI 10.1159/000298881

BJORO K, STRAYPEDERSEN S (1986)
INVITRO PERFUSION STUDIES ON HUMAN UMBILICAL ARTERIES .2. EFFECTS OF PROSTACYCLIN AND A THROMBOXANE-A2 MIMETIC
Acta Obstet. Gynecol. Scand., 65 (5), 467-471
DOI 10.3109/00016348609157387

BJORO K, STRAYPEDERSEN S (1986)
CHARACTERIZATION OF THE RESPONSES TO SEROTONIN AND PROSTANOIDS IN HUMAN UMBILICAL ARTERIES PERFUSED INVITRO
Scand. J. Clin. Lab. Invest., 46 184, 85-90

Bjøro K (1986)
Vasoactive substances and umbilicoplacental circulation: in vitro perfusion studies on human umbilical vessels
Department of Obstetrics and Gynaecology, Institute of Clinical Biochemistry, National Hospital, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 862138906, ISBN 82-991470-1-8

Bjøro K (1986)
Alt om svangerskapet: mor og barn uke for uke fra befruktning til fødsel
Schibsted, Oslo, 214 s.
BIBSYS 864046456, ISBN 82-516-1048-6

OGAARD AR, BJORO K, BUKHOLM G, BERDAL BP (1986)
PSEUDOMONAS-AERUGINOSA VIRULENCE FACTORS - MODIFICATIONS BY SUB-INHIBITORY CONCENTRATIONS OF CARBENICILLIN OR GENTAMICIN
ACTA PATH MICRO IM B, 94 (2), 63-68

RIVRUD GN, BERG K, ANDERSON D, BLOWERS S, BJORO K (1986)
STUDY OF THE AMNIOTIC-FLUID FROM SMOKERS AND NONSMOKERS IN THE AMES TEST
MUTAT RES, 169 (1-2), 11-16

RIVRUD GN, BERG K, ANDERSON D, BLOWERS S, BJORO K (1986)
MUTAGENIC EFFECT OF AMNIOTIC-FLUID FROM SMOKING WOMEN AT TERM
MUTAT RES, 171 (2-3), 71-77

Publications 1985

BERDAL BP, BJORO K, BUKHOLM G, OGAARD AR (1985)
PRESSURE-DEPENDENT AND TEMPERATURE-DEPENDENT ADHESION OF PSEUDOMONAS-AERUGINOSA TO HEP-2 CELLS
ACTA PATH MICRO IM B, 93 (2), 157-158

BJORO K (1985)
EFFECTS OF ANGIOTENSIN-I AND ANGIOTENSIN-II AND THEIR INTERACTIONS WITH SOME PROSTANOIDS IN PERFUSED HUMAN UMBILICAL ARTERIES
Prostaglandins, 30 (6), 989-998
DOI 10.1016/0090-6980(85)90171-6

BJORO K, BJORO K (1985)
DISTURBED INTRAUTERINE GROWTH IN TWINS - ETIOLOGICAL ASPECTS
ACTA GENET MED GEMEL, 34 (1-2), 73-79
DOI 10.1017/S0001566000004943

OGAARD AR, BJORO K, BUKHOLM G, BERDAL BP (1985)
CORRELATION BETWEEN ADHESION OF PSEUDOMONAS-AERUGINOSA BACTERIA TO CELL-SURFACES AND THE PRESENCE OF SOME FACTORS RELATED TO VIRULENCE
ACTA PATH MICRO IM B, 93 (3), 211-216

Publications 1984

BJORO K, MYHRE E (1984)
THE ROLE OF CHRONIC NON-SPECIFIC INFLAMMATORY LESIONS OF THE PLACENTA IN INTRA-UTERINE GROWTH-RETARDATION
ACTA PATH MICRO IM A, 92 (2), 133-137

Publications 1983

BJORO K (1983)
VASCULAR ANOMALIES OF THE UMBILICAL-CORD .1. OBSTETRIC IMPLICATIONS
Early Hum. Dev., 8 (2), 119-127

BJORO K (1983)
VASCULAR ANOMALIES OF THE UMBILICAL-CORD .2. PERINATAL AND PEDIATRIC IMPLICATIONS
Early Hum. Dev., 8 (3-4), 279-287

BJORO K, DYBVIK T (1983)
CONGENITAL-ABNORMALITIES AND GROWTH-PATTERNS AMONG CRYPTORCHIDIC BOYS
Ann. Chir. Gynaecol., 72 (6), 342-346

Björo K, Bjøro K (1983)
Barnløshet: årsaker og mulige behandlingsmetoder
Tiden, [Oslo], 94 s.
BIBSYS 835009866, ISBN 82-10-02421-3

Publications 1982

Madders J, Bjøro K (1982)
Stress og avspenning: hvordan du selv kan bekjempe stress og unngå nervøs spenning, mavesår, søvnløshet, migrene og høyt blodtrykk
Schibsted, Oslo, S.[3]-121
BIBSYS 832006904, ISBN 82-516-0853-8

Publications 1981

BJORO K (1981)
GROSS PATHOLOGY OF THE PLACENTA IN INTRAUTERINE GROWTH-RETARDATION
Ann. Chir. Gynaecol., 70 (6), 316-322

ROSSAVIK IK, BJORO K (1981)
THE PRENATAL DETERMINATION OF FETAL WEIGHT BY DYNAMIC SCANNING
Early Hum. Dev., 5 (2), 133-138
DOI 10.1016/0378-3782(81)90044-X

Publications 1979

Ree T, Bjøro K (1979)
Kompendium i karbohydrater
Institutt for medisinsk biokjemi, Oslo (2. utg.), 34 bl.
BIBSYS 950464597

Publications 1973

VANDERHAGEN CB, BORRESEN AL, MOLNE K, OFTEDAL G, BJORO K, BERG K (1973)
METACHROMATIC LEUKODYSTROPHY .1. PRENATAL DETECTION OF ARYLSULFATASE-A DEFICIENCY
Clin. Genet., 4 (3), 256-259